# NEURORECEPTOR MECHANISMS IN BRAIN

# NEURORECEPTOR MECHANISMS IN BRAIN

### Edited by

## Shozo Kito

University of the Air Chiba, Japan

# Tomio Segawa

Hiroshima University School of Medicine Hiroshima, Japan

#### and

# Richard W. Olsen

University of California-Los Angeles School of Medicine Los Angeles, California

PLENUM PRESS • NEW YORK AND LONDON

#### Library of Congress Cataloging in Publication Data

International Symposium on Neurotransmitter Receptors (3rd: 1990: Hiroshima-shi, Japan) Neuroreceptor mechanisms in brain / edited by Shozo Kito, Tomio Segawa, and Richard W. Olsen.

p. cm. - (Advances in experimental medicine and biology; v. 287)

"Proceedings of the Third International Symposium on Neurotransmitter Receptors, held February 5-8, 1990, in Hiroshima, Japan"—T.p. verso.

Includes bibliographical references.

Includes index.

ISBN 0-306-43821-6

1. Neurotransmitter receptors—Congresses. 2. Brain—Congresses. I. Kitō, Shōzō, date. II. Segawa, Tomio, 1927—. III. Olsen, Richard W. IV. Title. V. Series.

[DNLM: 1. Brain-physiology-congresses. 2. Receptors, Synaptic-physiology-congresses. W1 AD559 v. 287 / WL 300 I61243n 1990]

QP364.7.159 1990

612.8'22 - dc20

DNLM/DLC

for Library of Congress

91-3019

CIP

Proceedings of the Third International Symposium on Neurotransmitter Receptors, held February 5-8, 1990, in Hiroshima, Japan

ISBN 0-306-43821-6

© 1991 Plenum Press, New York A Division of Plenum Publishing Corporation 233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

#### FOREWORD

The Third International Symposium on Neurotransmitter Receptors was held in Hiroshima at a time when the entire field of neurotransmitter receptors in the brain is progressing at an unprecedented pace. The symposium also marked my retirement as Professor and Chairman of the Third Department of Internal Medicine, Hiroshima University School of Medicine, and a new beginning as a Professor of the University of the Air.

The symposium was remarkably successful, and there were enthusiastic responses from scientists all over the world, proving that the meeting was timely. The selected papers contained in this volume constitute a state-of-the-art survey of the most advanced aspects of neurotransmitter receptor mechanisms in the brain.

I owe thanks for the great success of the symposium to Prof. Richard Olsen of UCLA, Prof. Tomio Segawa of Hiroshima University, Prof. Kinya Kuriyama of Kyoto Prefectural University of Medicine, and Prof. Masaya Tohyama of Osaka University. I express my sincere gratitude to many friends for making this publication possible. I especially thank Dr. Rie Miyoshi, whose devoted efforts as secretary-general were vital to the success of the symposium. Dr. Miyoshi is currently an instructor in the Department of Pharmacology at Tokyo Women's Medical College. I would also like to acknowledge the excellent secretarial work of Misses Ritsuko Sato and Yuko Wakita.

My appointment to the University of the Air affords me access to a well-equipped laboratory for basic biological research. I hope that my concentration on receptor studies over the next several years will make it possible for me to organize the Fourth International Symposium on Neuro-transmitter Receptors, probably not at Hiroshima, but at the University of the Air, which is located close to the Tokyo metropolitan area.

Finally, this symposium was financially supported by the Japanese Ministry of Science, Culture, and Education.

Shozo Kito

#### PREFACE

The Third International Symposium on Neurotransmitter Receptors, held in Hiroshima, Fabruary 5-8, 1990, continues the tradition of the first two such symposia held in 1983 and 1987, also published by Plenum Press. However, the fame of these meetings has obviously been growing, as indicated by both the large number of abstracts received and the great number of countries represented by the attending neuroscientists.

The topics covered in this publication of the proceedings include structural and functional studies on some well-characterized receptor proteins, and characterization of receptor-coupling mechanisms, receptor interactions, and receptor regulation, with concentration on the central nervous system. Techniques described include now-classical molecular pharmacology through imaging of second messengers in cells and in intact brain to the most sophisticated use of recombinant DNA technology. Readers will no doubt find these representative chapters at the cutting edge of neuroscience.

Speaking on behalf of the participants at the Hiroshima symposium, I would like to thank Professor Kito sincerely and warmly for providing this excellent scientific program in the midst of an extremely friendly and enjoyable visit to Japan. I hope that there will be more such occasions.

Richard W. Olsen

#### CONTENTS ~

Effect of Neuropeptides on Classic Types of Neurotransmission	
in the Rat Central Nervous System	4
S. Kito and R. Miyoshi	1
Solubilization and Characterization of Substance P Receptors in the Central Nervous System	
T. Segawa and Y. Nakata	13
Evidence for Cardiovascular Roles of Tachykinin Peptides in the Brain of the Rat	
H. Kamiya, Y. Takano, and A. Nagashima	. 27
Functions of a Co-Transmitter, Calcitonin Gene-Related Peptide, on the Neuromuscular Junction	¥.
S. Uchida, K. Takami, H. Kobayashi, K. Hashimoto, and N. Matsumoto	39
Pharmacological Characterization of Sigma Binding Sites in Guinea Pig Brain Membranes E.W. Karbon and S.J. Enna	
E.w. Karbon and S.J. Enna	51
Transmitter-Activated Ion Channels as the Target of Chemical Agents T. Narahashi	61
Chemical Kinetic Investigations of the Channel-Opening Process of Neurotransmitter Receptors N. Matsubara, A.P. Billington, H.C. Chen, A.P. Guzikowski, K.W. Johnson, D. Ramesh, M.T. Sweet, and G.P. Hess	75
Primary Structure and Functional Expression of the Inositol 1,4,5-Trisphosphate Receptor, P400 K. Mikoshiba, T. Furuichi, N. Maeda, S. Yoshikawa, A. Miyawaki, M. Niinobe, and K. Wada	83
Inositol 1,4,5-Trisphosphate Activates Ca <sup>2+</sup> Channels in the Plasma Membranes of Rat Brain Nerve Terminals M. Satoh, H. Ueda, S. Tamura, Y. Yoshihara, and	
N. Fukushima	97
Formation of Inositol Polyphosphates in Cultured Adrenal Chromaffin Cells	al .
N. Sasakawa, T. Nakaki, and R. Kato	111
Effects of Oxygen Depletion on Phosphoinositide Breakdown in	
Rat Brain Slices H. Ninomiya, T. Taniguchi, and M. Fujiwara	125

Expression of G-Protein ∝-Subunit cDNA T. Nukada	141
Serotonin Receptor Subtypes in Brain: Ligand Binding Properties and Coupling with G Proteins Y. Nomura, Y. Kitamura, M. Tohda, S. Imai, T. Katada, and M. Ui	151
A Cerebral Endogenous Factor Regulates the Activity of the Serotonergic Receptors Modulating the Neuronal Release of Acetylcholine G. Fillion, P. Barone, I. Cloëz, M.P. Fillion, C. Harel,	
O. Massot, J.C. Rousselle, and E. Zifa	165
Serotonin Receptor Heterogeneity and the Role of Potassium Channels in Neuronal Excitability J.S. Kelly, P. Larkman, N.J. Penington, D.G. Rainnie, H. McAllister-Williams, and J. Hodgkiss	177
Modulatory Actions of Norepinephrine on Neural Circuits D.J. Woodward, H.C. Moises, B.D. Waterhouse, H.H. Yeh, and J.E. Cheun	193
Genetic Analysis of the $eta$ -Adrenergic Receptor C.D. Strader and R.A.F. Dixon	209
Reversal of Nigrostriatal-Lesion-Induced Receptor Alterations by Grafting of Fetal Mesencephalic Dopaminergic Neurons J.K. Wamsley, T.M. Dawson, V.L. Dawson, M.A. Hunt, L.J. Fisher, and F.H. Gage	221
Octopamine: An Endogenous Blocker of Dopamine D-1 Receptors J.T. Cheng and J.T. Tsai	237
Depression of NMDA-Evoked Acetylcholine Release by Endogenous Adenosine in Striatum Slices E. Porsche and T. Schwan	241
Imaging of Dopamine D1 and D2 Receptors by a High Resolution Positron Emission Tomography	
H. Shinotoh, A. Aotsuka, O. Inoue, K. Suzuki, H. Fukuda, M. Iyo, T. Yamazaki, Y. Tateno, K. Hirayama, and N. Nohara	249
The Nicotinic Acetylcholine Receptor Gene Family: Structure of Nicotinic Receptors from Muscle and Neurons and Neuronal &-Bungarotoxin-Binding Proteins	
J. Lindstrom, R. Schoepfer, W. Conroy, P. Whiting, M. Das, M. Saedi, and R. Anand	255
Regulation of the Nicotinic Acetylcholine Receptor by Serine and Tyrosine Protein Kinases R.L. Huganir	279
Affinity Purification of Nicotinic Acetylcholine Receptor from Rat Brain	
H. Nakayama, J. Lindstrom, T. Nakashima, and Y. Kurogochi	295
Differential Coupling of Subtypes of the Muscarinic Receptor to Signaling Mechanisms in Brain and Peripheral Tissues	301-

1,

The Molecular Properties of the M <sub>1</sub> Muscarinic Receptor and its Regulation of Cytosolic Calcium in a Eukaryotic Gene Expression System	
J. Lai, T.L. Smith, L. Mei, M. Ikeda, Y. Fujiwara, J. Gomez, M. Halonen, W.R. Roeske, and H.I. Yamamura	313
Molecular Mechanism Underlying the Occurrence of Supersensitivity at Muscarinic Receptors: Analysis Using Cerebral Cortical Neurons in Primary Culture	. ·
K. Kuriyama and S. Ohkuma	331
Super-Delayed Changes of Muscarinic Acetylcholine Receptor in the Gerbil Hippocampus Following Transient Ischemia N. Ogawa, K. Haba, M. Asanuma, K. Mizukawa, and A. Mori	343
Intramembrane Particles in the Postsynaptic Membranes of the S-, F-, and C-Type Synapses by Freeze-Fracturing, and Deep-Etching Studies on the Xenopus Spinal Cord H. Watanabe, H. Washioka, and A. Tonosaki	349
GABA - Benzodiazepine Receptors: Demonstration of Pharmacological	
R.W. Olsen, M. Bureau, S. Endo, G. Smith, L. Deng, D. Sapp, and A.J. Tobin	355
Structural, Developmental, and Functional Heterogeneity of Rat GABA, Receptors	
A.J. Tobin, M. Khrestchatisky, A.J. MacLennan, M.Y. Chiang, N.J.K. Tillakaratne, W. Xu, M.B. Jackson, N. Brecha, C. Sternini, and R.W. Olsen	365
Subunit and Subtype-Specific Antibodies to the GABA-A/Benzodiazepine Receptor Complex	
S. Endo and R.W. Olsen	375
The Differential Expression Pattern of the mRNAs Encoding β Subunits (β <sub>1</sub> , β <sub>2</sub> and β <sub>3</sub> ) of GABA Receptor in Rat Brain J.H. Zhang, M. Sato, K. Noguchi, and M. Tohyama	381
"In Vivo" Inhibition of GABAergic Transmission Increases 35S-TBPS Binding in the Rat Brain	. 5.4
G. Biggio, E. Sanna, M. Serra, G.P. Serra, and A. Concas	391
123-I-Iomazenil-SPECT in Patients with Focal Epilepsies - A Comparative Study with Tc-HMPAO-SPECT, CT and MR F.J. Ferstl, M. Cordes, I. Cordes, H. Henkes, W. Christe, H. Eichstädt, G. Barzen, B. Schmitz, P.H. Hasler, P.A. Schubiger, D. Schmidt, and R. Felix	405
Expression of the GABA <sub>B</sub> Receptor in Xenopus Oocytes and Desensitization by Activation of Protein Kinase C	
K. Taniyama, K. Takeda, H. Ando, and C. Tanaka	413
Structure and Expression of Inhibitory Glycine Receptors H. Betz, D. Langosch, W. Hoch, P. Prior, I. Pribilla, J. Kuhse, V. Schmieden, ML. Malosio, B. Matzenbach, F. Holzinger, A. Kuryatov, B. Schmitt, Y. Maulet, and	
CM. Becker	421

Heterogeneous Distribution of Glutamate Receptor Subtypes in Hippocampus as Revealed by Calcium Fluorometry	
Y. Kudo, E. Ito, and A. Ogura 4	31
Excitatory Amino Acid Receptors in the Xenopus Oocyte	
Expression System R. Dingledine, N.W. Kleckner, and C.J. McBain 4	41
Novel Fourth Binding Sites of [3H] Spermidine within the NMDA Receptor Complex	
Y. Yoneda and K. Ogita 4	55
Solubilization of the NMDA Receptor Ion Channel Complex from Rat Brain	
K. Ogita and Y. Yoneda 4	77
NMDA Receptor Agonists: Relationships between Structure and Biological Activity	
	83
Contributors4	89
Index4	95

EFFECT OF NEUROPEPTIDES ON CLASSIC TYPES OF NEUROTRANSMISSION IN THE RAT

Shozo Kito and Rie Miyoshi

Third Department of Internal Medicine, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minamiku, Hiroshima 734 Japan

#### INTRODUCTION

Neuromodulator is a term for which there is no clear definition. For the past several years, the authors have been studing how neuropeptides modulate classic types of neurotransmission. We observed two examples of peptide action, that is, an effect of somatostatin on muscarinic acetylcholine receptors (mAChR) and that of cholecystokinin (CCK) on dopamine receptors in the rat brain, and obtained results suggesting that these two peptides modulated classical neurotransmitter receptors in a similar manner.

Both acetylcholine (Coyle et al., 1983; Perry et al., 1977) and somatostatin (Beal et al., 1986; Roberts et al., 1985) were definitely diminished in the brain of Alzheimer's disease. Morphologically, it has been reported that septo-hippocampal cholinergic neurons project to somatostatin-containing neurons in the hippocampus (Yamano and Luiten, 1989). In addition, it has been reported that somatostatin affects the turnover rate of acetylcholine in this brain area (Wood et al., 1981). Within the hippocampus, there are abundant MI subtype mAChR (Vickroy et al., 1984). The authors investigated a modulatory effect of somatostatin on mAChR and an intracellular response after somatostatin receptor activation in the rat hippocampus from the viewpoint of pharmacology.

CCK receptors are observed richly in the striatum where dopaminergic nerve terminals ascending from the substantia nigra are observed with high density (Gaudreau et al., 1985). There has been strong evidence for dopamine and CCK interaction in the basal ganglia. For instance, CCK coexists with dopamine in the midbrain region (Hommer 1986), and the peptide modulates dopamine release striatum (Hokfelt et al., 1985; Kovacs et al., 1981; Starr, 1982). Dopamine receptors have been classified into two major subtypes on the basis of their pharmacological and biochemical characteristics (Leff and Creese, 1983; Stoof and Kebabian, 1984). The functional significance of D2 receptors in the central nervous system has been well discussed from the viewpoints of pharmacotherapy of psychosis and movement disorders. Recently, availability of Dl selective ligands has made it possible study physiological roles of D1 receptors in the central nervous system (Iorio et al., 1983). In the present paper, the effect of CCK on D1

receptor binding and the intracellular transduction system of CCK receptors were examined in the rat striatum.

#### MATERIALS AND METHODS

#### Effect of Somatostatin on mAChR in the Hippocampus

Wistar strain male rats weighing 200-250 g were used in these experiments. After decapitation, the hippocampus was rapidly removed and P<sub>2</sub> fractions of the tissue were prepared. Both H-QNB and H-N-methyl-scopolamine (NMS) were used as mAChR antagonists. For observation of mAChR agonist binding sites, oxotremorine/H-NMS inhibition experiments were performed. As assay medium, Krebs-Henseleit solution containing bovine serum albumin, bacitracin and pepstatin was used. Non-specific binding was defined as the binding in the presence of 1 µM atropine. Aliquots of the tissue preparation were incubated at 30°C for 15 min. Membrane bound H-ligands were trapped by the rapid vacuum filtration method.

The phosphatidylinositol (PI) turnover is one of the important second messenger systems involving an increase of intracellular Carconcentration ([Ca<sup>2+</sup>]i) and activation of protein kinase C (Berridge and Irvine, 1984; Nishizuka, 1986). There has been strong evidence that mAChR activate this signal transduction system in various tissues (Brown et al., 1984; Janowsky et al., 1984). In this experiment, the synergistic effect of carbachol, a mAChR agonist, and somatostatin was investigated using hippocampal slices according to Berridge's method.

In addition, changes of [Ca<sup>2+</sup>]i in response to somatostatin were examined by fura-2 fluorometry on a single cell basis. Hippocampal neurons were obtained from 18-day rat embryos and dissociated cell cultures were made. Cultures were maintained for 12-14 days. After 3 days in vitro, cultures were treated with 10 µM cytosine arabinofuranoside for 24 hrs in order to suppress growth of fibroblasts and glial cells. The level of [Ca<sup>2+</sup>]i was measured in combination of fura-2, a fluorescence microscope, a video camera and photometrical devices as previously described (Kudo et al., 1986). Drugs used in this experiment were applied to cultured neurons by perfusion. During measurement, 1 µM tetrodotoxin was added to a buffer in order to block spontaneous Ca<sup>2+</sup> flux. The amount of [Ca<sup>2+</sup>]i was quantitatively determined by a dual beam excitation method.

#### Effect of CCK on Dopamine Dl Receptors in the Striatum

For dopamine D1 receptor binding, the P<sub>2</sub> fraction of the striatum was used. H-SCH23390 was used as a D1 selective antagonist. For gbservation of D1 antagonist binding sites, saturation experiments with H-SCH23390 were performed. Non-specific binding was defined as binding in the gresence of 10<sup>-5</sup> M SCH23390. For D1 agonist binding sites, dopamine/H-SCH23390 inhibition experiments were done. As assay medium, 50 mM Tris HCl buffer, pH7.4 containing 5 mM KCl, 1 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, bovine serum albumin and bacitracin was used. Aliquots of the tissue preparation were incubated at 22°C for 30 min.

To study intracellular responses of CCK receptors, changes of the PI turnover-Ca signalling system in response to either CCK-8 or ceruletide, an octapeptide analog of CCK-8, were examined with use of the rat striatum.

#### Effect of Somatostatin on mAChR in the Hippocampus

Somatostatin had no effect on both  $^3\text{H-QNB}$  and  $^3\text{H-NMS}$  binding in the rat hippocampus (data not shown). However, as shown in Fig. 1, the peptide affected the affinity of agonist binding sites. An oxotremorine/ $^3\text{H-NMS}$  inhibition curve exhibited heterogeneous characteristics with a Hill coefficient much less than 1. The binding data were fitted best by a two-site model, characterized by two dissociation constants: a K<sub>H</sub> value of  $6.6\text{x}10^{-9}$  M and a K<sub>L</sub> value of  $2.6\text{x}10^{-9}$  M. Percentages of high and low affinity binding sites to the total binding capacity were  $36.3~\%_8$  and  $63.7~\%_8$ , respectively. The inhibition curve after adding 1 µM [D-trp ] somatostatin in the incubation medium exhibited a Hill slope factor close to 1, and the curve fitted best to a binding model consisting of a single homogeneous binding site whose Ki value was consistent with the K<sub>T</sub> value.

As previously reported by various groups (Brown et 3al., 1984; Janowsky et al., 1984), carbachol caused an enhancement of H-inositol-l-phosphate (IP $_{\rm l}$ ) accumulation. Somatostatin significantly augmented the effect of carbachol (p<0.01), while somatostatin itself had no effect on the basal accumulation of  $^{\rm H-IP}_{\rm l}$  (Fig. 2).

As the next step, to elucidate the mechanism of the above-mentioned effects of somatostatin on mAChR, changes of  $[Ca^2]$  i in response to somatostatin were examined in cultured hippocampal neurons. Fig. 3 shows the response to either  $[D-trp^6]$  somatostatin or SMS201-995 at the concentration of  $10^{-5}$  M in the same cultured hippocampal neuron. The basal glevel of  $[Ca^2]$  i in neurons was about 100 nM. By perfusing with  $[D-trp^6]$  somatostatin for 30 sec., a monophasic increase of  $[Ca^2]$  i was observed. The cell population which responded to  $[D-trp^6]$  somatostatin stimulation was 26.5 % of the total neurons. SMS201-995, a very potent octapeptide analog of somatostatin, had about 2 times more potency on elevation of  $[Ca^2]$  i. This effect of somatostatin was found to be dose-dependent when concentrations ranging from  $10^{-6}$  to  $10^{-6}$  M were used. As next experiments, the  $Ca^2$  source for the effect of somatostatin was determined. Fig. 4 shows changes of  $[Ca^2]$  i in response to  $[D-trp^6]$  somatostatin in cases of perfusing with either normal buffer or  $Ca^2$  -depleted medium in the same neuron. The effect of somatostatin was completely blocked in  $Ca^2$  -depleted medium. The




Fig. 1 Oxotremorine binding to P<sub>2</sub> fraction of the rat hippocampus measured by competition with H-NMS in the presence and absence of 1  $\mu$ M [D-trp 1 somatostatin. n<sub>H</sub>: Hill coefficient. The concentration of H-NMS was 0.2 nM. These values were means in 3 repeated experiments.




Fig. 2 Effect of [D-trp<sup>8</sup>]somatostatin on carbachol-stimulated inositol phospholipid hydrolysis in rat hippocampal slices. The concentrations of carbachol and somatostatin were 1 mM and 50 μM, respectively. Somatostatin augmented carbachol-induced accumulation of H-IP, in a dose-dependent manner (data not shown). Values represent % of those in experiments in which 10 mM LiCl alone was added to the incubation medium. p<0.05, vs the data with 1 mM carbachol. n=3.




Fig. 3 Effect of  $10^{-5}$  M  $[D-trp^8]$  somatostatin (SS) or SMS201-995 on  $[Ca^{2+}]i$  in the same cultured rat hippocampal neuron. Drugs were applied to the neuron by perfusion for 30 sec.





Fig. 4 Determination of the source of Ca<sup>2+</sup> for [D-trp<sup>8</sup>]somatostatin (SS)-induced elevation of [Ca<sup>2+</sup>]i in cultured rat hippocampal neurons. The upper plate shows a result of an experiment perfusing with normal buffer and the middle Ca<sup>2+</sup>-depleted medium. In the latter case, the neuron was perfused for 1 min with Ca<sup>2+</sup>-depleted medium in which CaCl<sub>2</sub> was removed and 0.1 mM EGTA was added, prior to SS stimulation. The lower plate shows recovery of the response by re-perfusing with normal buffer.






Fig. 5 Effect of  $\omega$ -conotoxin GVIA on  $[D-trp^8]$  somatostatin (SS)-induced increase of  $[Ca^{2+}]$  i in cultured rat hippocampal neurons. The upper plate shows a result of an experiment perfusing with normal buffer and the lower that of pretreatment with l  $\mu$ M  $\omega$ -conotoxin GVIA for l min. A set of experiments were performed using the same neuron.

binding sites without changing dissociation constants, independently. In the presence of NaCl, CCK-8 caused further conversion to a low affinity state. However, when both GTP and CCK-8 were added, CCK-8 did not convert anymore.

#### Effect of CCK on Dopamine Dl Receptors in the Striatum

Scatchard analysis revealed that  $^3\text{H-SCH23390}$  had a single high affinity binding site whose Kd and Bmax values were 1.57 nM and 907.6 fmol/mg protein, respectively. CCK-8 at the concentration of 1  $\mu$ M had no effect on  $^3\text{H-SCH23390}$  binding (data not shown).

Table 1 shows results obtained from dopamine/ $^3$ H-SCH23390 inhibition experiments in the rat striatum. Curves without and with CCK-8 exhibited heterogeneous characteristics with Hill coefficients much less than 1. In the absence of CCK-8, the binding data were fitted best by a two-site model, characterized by two dissociation constants: a K<sub>H</sub> value of 7.76x10 M and a K<sub>L</sub> value of 2.45x10 M. Percentages of high (R<sub>H</sub>) and low (R<sub>L</sub>) affinity binding sites to the total binding capacity were 74.6 and 25.4 %, respectively. After adding 1 µM CCK-8, R<sub>H</sub> decreased to 51.3 % and R, increased to 48.7 %, with their affinity constants unchanged. Guanine nucleotides and sodium ion have been known to convert agonist high affinity binding sites into low affinity ones striatal dopamine receptors (Grigoriadis and Seeman, 1985). mechanism of the effect of guanine nucleotides on agonist binding has been well investigated and accepted to be the result of the dissociation of a GTP binding protein from a receptor protein. The mechanism of sodium ion is not yet clear, but it is suggested that sodium ion acts like an allosteric inhibitor of dopamine receptors. In our experiments, both 50 µM GTP and 120 mM NaCl caused a reduction of high affinity

Table 1. Effect of CCK-8, NaCl and GTP on dopamine binding to the rat striatum measured by competition with 3H-SCH23390

	n <sub>H</sub>	-log[K <sub>H</sub> ]	-log[K <sub>L</sub> ]	R <sub>H</sub> (%)	R <sub>L</sub> (%)
	0.64 ± 0.10	6.11 ± 0.53	4.61 ± 0.17	74.60 ± 1.44	25.40 ± 1.44
CCK-8	0.75 ± 0.06	7.02 ± 0.09	5.67 ± 0.14	51.27 ± 5.83	48.73 ± 5.83
NaCl	0.67 ± 0.04	6.17 ± 0.01	4.73 ± 0.10	55.61 ± 0.81	44.39 ± 0.81
NaCl + CCK-8	0.73 ± 0.02	6.91 ± 0.26	5.05 ± 0.04	27.61 ± 4.81	72.39 ± 4.81
GTP	0.71 ± 0.20	6.99 ± 1.47	4.93 ± 0.49	48.13 ± 7.53	51.87 ± 7.53
GTP + CCK-8	0.70 ± 0.04	6.97 ± 0.43	5.41 ± 0.14	45.94 ± 9.29	54.06 ± 9.29

Synergistic effects of CCK-8 and NaCl or GTP on dopamine/ $^3$ H-SCH23390 inhibition experiments were studied in rat striatal homogenates. These drugs were added to the incubation medium. These values were means of 3 repeated experiments.




Fig. 6 Effect of various concentrations of ceruletide on [Ca<sup>2+</sup>]i in the same cultured rat striatal neuron. Ceruletide was applied to the neuron by perfusion for 30 sec.

blockage was recovered by re-perfusing with the normal buffer. After l min pretreatment with l  $\mu$ M  $\omega$ -conotoxin GVIA, a neurotoxic peptide from the verom of a marine snail, the effect of somatostatin was completely inhibited (Fig. 5). Nifedipine, one of the dihydropyridine Ca channel blockers, had no effect on the [Ca channel of the control of th

Using the same experimental process as in the case of somatostatin, the authors investigated the effect of CCK on the PI turnover-Ca'signalling system in the rat striatum. Neither CCK-8 nor ceruletide changed basal PI turnover. However, ceruletide caused a monophasic increase of [Ca'] i in a dose-dependent manner as shown in Fig. 6. The response to ceruletide was completely blocked by perfusing with Ca'-depleted medium or pretreatment with  $\omega$ -conotoxin GVIA.

#### DISCUSSION

Since the effect of somatostatin on mAChR in the 'rat hippocampus was limited to agonist binding, it seems that somatostatin dose not bind mAChR directly, but the peptide affects the functional state of receptors through some intracellular responses.

Somatostatin has been considered to be an inhibitory neuropeptide throughout the endocrine and nervous systems. As for the intracellular response, somatostatin inhibits adenylate cyclase activity and  $Ca^{+}$ 

mobilization in the pituitary, pancreas and so on (Catalan et al., 1979; Chneiweiss et al., 1987; Diez and Tamargo, 1987; Luini et al., 1986). In our experiments, in the presence of somatostatin, the muscarinic function seems to be activated, that is, a reduction of the affinity of receptors and augmentation of PI turnover elicited by a mAChR agonist in the hippocampus occur. In previous reports, an excitatory effect of somatostatin has been described in the hippocampus and cerebral cortex from viewpoints of electrophysiology (Dodd and Kelly, 1978; Ioffe et al., 1978; Olpe et al., 1980). In this paper, as a novel excitatory response of somatostatin, the authors obtained results that the peptide increased [Ca<sup>2+</sup>]i, probably via N-type Ca<sup>2+</sup> channels. It is considered that an increase of [Ca<sup>2+</sup>]i induced by somatostatin is a key event for modulating the muscarinic function.

Galanin is a neuropeptide which is considered to have some relation to the septo-hippocampal cholinergic system (Dutar et al., 1989; Melander et al., 1985; Senut et al., 1989). Consolo et al. reported that galanin reduced PI turnover elicited by carbachol probably because of its lowering action of [Ca<sup>2+</sup>]i in the rat hippocampus (Consolo et al., 1989). The authors confirmed that galanin decreased [Ca<sup>2+</sup>]i stimulated by high K (unpublished data). A possible mechanism on modulation of hippocampal mAChR by neuropeptides is schematically shown in Fig. 7.

Our indirect agonist binding studies revealed that CCK-8 converted a part of Dl agonist high affinity binding sites into low affinity ones in the rat striatum. It was noticed that the effect of CCK-8 was similar to that of GTP rather than that of NaCl. Therefore, it is considered that CCK-8 modulates Dl agonist binding sites in a GTP-like manner. It is noteworthy that somatostatin and CCK exert the same kind of effect on classical neurotransmission, that is, these two peptides reduce the affinity of agonist binding for muscarinic and Dl receptors,

Regulation of mAChR-coupled PI turnover by peptides in the hippocampus




Fig. 7 A possible scheme for regulation of mAChR-induced stimulation of PI turnover by neuropeptides. It seems that the hippocampal mAChR function is regulated by at least two neuropeptides, that is, somatostatin and galanin, in an opposite manner.